Drug Safety Assessment of Medication Accumulation During Organ Support and Extracorporeal Therapies in Critical Illness

Abstract

Medication accumulation in critically ill patients undergoing organ support and extracorporeal therapies poses significant drug safety concerns, impacting pharmacokinetics, pharmacodynamics, and therapeutic efficacy. This review examines the epidemiology, pathophysiology, risk factors, clinical features, diagnostic strategies, and management approaches for drug accumulation during interventions such as renal replacement therapy (RRT) and extracorporeal membrane oxygenation (ECMO). Recent advances, emerging therapies, and current guideline recommendations are discussed, providing evidence-based insights for clinicians to optimize patient outcomes and minimize adverse drug events in the intensive care setting.

Introduction

In the intensive care unit (ICU), the complexity of multi-organ dysfunction, frequent use of high-risk medications, and implementation of advanced organ support modalities such as RRT and ECMO introduce significant challenges in drug dosing and safety. Drug accumulation, resulting from altered pharmacokinetics and pharmacodynamics, increases the risk of toxicity and therapeutic failure. A systematic understanding of the mechanisms, risk factors, and clinical implications of drug accumulation is essential for optimizing pharmacotherapy in critically ill patients. This review synthesizes current evidence and guideline-based strategies for drug safety assessment during organ support and extracorporeal therapies.

Epidemiology / Disease Burden

The prevalence of organ dysfunction requiring advanced support in critical illness is rising, with acute kidney injury (AKI) affecting 20-50% of ICU patients, and up to 10% of these requiring some form of RRT. Similarly, ECMO utilization has increased for refractory cardiac and respiratory failure. These interventions, while life-saving, are associated with significant alterations in drug handling; studies report that up to 60% of ICU patients on RRT or ECMO experience at least one adverse drug event related to inappropriate dosing or accumulation. The burden is compounded by polypharmacy, frequent empirical antimicrobial therapy, and the use of narrow therapeutic index agents.

Pathophysiology

Drug accumulation during organ support arises from multiple mechanisms. In AKI, impaired renal clearance leads to the retention of renally-excreted drugs and active metabolites. RRT modifies elimination kinetics, variably removing drugs depending on modality (e.g., continuous vs intermittent), membrane characteristics, and drug properties (e.g., molecular weight, protein binding). ECMO circuits can sequester or adsorb lipophilic and protein-bound drugs, altering volume of distribution and clearance. Organ dysfunction further disrupts hepatic metabolism, plasma protein levels, and tissue perfusion, compounding unpredictability in drug exposure. The interplay between critical illness, organ support modality, and drug characteristics necessitates individualized pharmacokinetic considerations.

Risk Factors

Several risk factors increase susceptibility to drug accumulation during organ support. These include advanced age, low body weight, hypoalbuminemia, pre-existing organ dysfunction, polypharmacy, and the use of high-risk medications such as antimicrobials, antiepileptics, and anticoagulants. The type and intensity of extracorporeal therapy, circuit composition, and duration of support further modulate risk. Notably, critically ill patients often exhibit highly variable and dynamic physiology, further challenging standardized dosing.

Clinical Features

Clinical manifestations of drug accumulation are diverse, ranging from subtle neurocognitive changes and gastrointestinal symptoms to severe organ toxicity (e.g., nephrotoxicity, hepatotoxicity, arrhythmias, bleeding). Symptoms may be masked by the underlying critical illness or attributed to other etiologies, underscoring the need for high clinical vigilance. Laboratory markers (e.g., elevated drug levels, abnormal liver or renal function tests) and the development of unexpected side effects should prompt evaluation for drug accumulation.

Diagnosis

Diagnosis of drug accumulation relies on a combination of clinical assessment, therapeutic drug monitoring (TDM), and review of pharmacokinetic parameters. TDM is particularly valuable for medications with narrow therapeutic indices (e.g., vancomycin, aminoglycosides, anticonvulsants) and for those with unpredictable clearance in the setting of organ support. Interpretation of drug levels must account for assay timing, modality-specific clearance, and the patient’s evolving clinical status. Diagnostic stewardship, including review of all administered medications and dosing regimens, is integral to identifying and mitigating drug accumulation.

Treatment & Management

Management strategies center on individualized dosing adjustments, guided by TDM, pharmacokinetic modeling, and multidisciplinary collaboration. Dose modification based on organ function, route of administration, and modality-specific drug removal is essential. For RRT, considerations include drug molecular size, protein binding, and filter characteristics. In ECMO, circuit-related sequestration may necessitate higher initial dosing or alternative agents. Regular review of medication necessity, early de-escalation, and prompt recognition of toxicity or subtherapeutic exposure are critical. Supportive care and, when necessary, enhanced extracorporeal drug clearance (e.g., hemoperfusion) may be employed in cases of severe toxicity.

Recent Advances / Emerging Therapies

Recent years have witnessed advances in pharmacokinetic modeling, real-time TDM, and integration of clinical decision support systems to guide drug dosing in critically ill patients. Population pharmacokinetic models and Bayesian forecasting are increasingly used to predict drug exposure in complex scenarios, including during RRT and ECMO. Novel extracorporeal circuits with reduced drug adsorption and improved biocompatibility have been developed. Research is ongoing into the use of biosensors and point-of-care assays for rapid drug level measurement, facilitating timely dose adjustment. Ongoing clinical trials are evaluating optimal dosing strategies for new and existing agents in patients receiving advanced organ support.

Guideline Recommendations

International guidelines, including those from the Kidney Disease: Improving Global Outcomes (KDIGO) and the Extracorporeal Life Support Organization (ELSO), emphasize the importance of individualized drug dosing, regular TDM, and multidisciplinary review in patients on organ support. Key recommendations include early identification of at-risk patients, selection of appropriate drug regimens, and frequent reassessment of pharmacotherapy in response to changes in organ function and extracorporeal therapy parameters. Guidelines advocate for institutional protocols, education of clinical staff, and engagement of pharmacists in the ICU team to optimize safety and efficacy.

Conclusion

Drug accumulation during organ support and extracorporeal therapies in critical illness is a complex, multifactorial challenge with significant implications for patient safety and therapeutic outcomes. Clinicians must maintain high vigilance, utilize individualized pharmacokinetic approaches, and adhere to evidence-based guidelines to mitigate risks. Ongoing advances in pharmacological monitoring and extracorporeal technology promise to enhance drug safety assessment, but multidisciplinary collaboration and continual education remain cornerstones of optimal care in this evolving landscape.